Development of NGR-Based Anti-Cancer Agents for Targeted Therapeutics and Imaging

ISSN: 1875-5992 (Online)
ISSN: 1871-5206 (Print)

Volume 17, 14 Issues, 2017

Download PDF Flyer

Anti-Cancer Agents in Medicinal Chemistry

Formerly: Current Medicinal Chemistry - Anti-Cancer Agents

This journal supports open access

Aims & ScopeAbstracted/Indexed in

Ranking and Category:
  • 27th of 59 in Chemistry, Medicinal

Submit Abstracts Online Submit Manuscripts Online

Michelle Prudhomme
Institut de Chimie de Clermont-Ferrand
Université Clermont Auvergne

View Full Editorial Board

Subscribe Purchase Articles Order Reprints

Current: 2.722
5 - Year: 2.849

Development of NGR-Based Anti-Cancer Agents for Targeted Therapeutics and Imaging

Anti-Cancer Agents in Medicinal Chemistry, 12(1): 76-86.

Author(s): Rongsheng E. Wang, Youhong Niu, Haifan Wu, Yaogang Hu and Jianfeng Cai.

Affiliation: Department of Chemistry, University of South Florida, 4202 E. Fowler Ave, Tampa, FL 33620.


Besides the common issue of drug-resistance, the conventional approaches for cancer diagnostics and treatment are constantly challenged by poor selectivity and limited access to neoplastic cells, which not only lead to the dose-limiting effect on the tumor region, but also bring side-effects to healthy cells/tissues. In recent years, a novel strategy has arisen to target the vasculature of tumors for drugdelivery and molecular imaging, based on the success of anti-angiogenic therapy. In addition to being easily accessible, the endothelial cells of tumor vasculature are also genetically stable and thus do not develop drug-resistance, making them ideal targets for chemotherapeutics and biomedical imaging. Among various ligands identified so far, the Asn-Gly-Arg (NGR) tripeptide can specifically target the neovasculature via interaction with the aminopeptidase N (APN / CD13) receptor which is highly up-regulated in the membranes of endothelial tumor cells. NGR-directed drug delivery as well as molecular imaging have therefore been undergone development, and appear to be intriguing approaches in current cancer research. Herein we highlight some recent developments of the NGR peptide based cancer therapy including drug-delivery and imaging studies, with future perspectives. Some of these agents have been under clinical trials, indicating promising future for the NGR-based drugs.


Asn-Gly-Arg (NGR), Aminopeptidase N (APN / CD13), Angiogenesis, Drug delivery, Imaging, Cancer, Clinical trial, peptides, Human interferon, platinum derivatives.

Download Free Order Reprints Order Eprints Rights and Permissions

Article Details

Volume: 12
Issue Number: 1
First Page: 76
Last Page: 86
Page Count: 11
DOI: 10.2174/187152012798764714
Global Biotechnology Congress 2017Drug Discovery and Therapy World Congress 2017

Related Journals

Related eBooks

Webmaster Contact: Copyright © 2017 Bentham Science